Editas Medicine (EDIT) Leases (2019 - 2025)
Editas Medicine (EDIT) has disclosed Leases for 7 consecutive years, with $17.6 million as the latest value for Q3 2025.
- On a quarterly basis, Leases fell 50.79% to $17.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $17.6 million, a 50.79% decrease, with the full-year FY2024 number at $32.6 million, down 3.34% from a year prior.
- Leases was $17.6 million for Q3 2025 at Editas Medicine, down from $19.0 million in the prior quarter.
- In the past five years, Leases ranged from a high of $43.6 million in Q4 2022 to a low of $17.6 million in Q3 2025.
- A 5-year average of $29.5 million and a median of $30.3 million in 2021 define the central range for Leases.
- Peak YoY movement for Leases: surged 68.45% in 2023, then plummeted 50.79% in 2025.
- Editas Medicine's Leases stood at $26.2 million in 2021, then skyrocketed by 66.77% to $43.6 million in 2022, then decreased by 22.84% to $33.7 million in 2023, then dropped by 3.34% to $32.6 million in 2024, then crashed by 45.99% to $17.6 million in 2025.
- Per Business Quant, the three most recent readings for EDIT's Leases are $17.6 million (Q3 2025), $19.0 million (Q2 2025), and $26.4 million (Q1 2025).